Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Gentian Diagnostics ASA ( (DE:6FK) ) has issued an update.
Gentian Diagnostics ASA reported a strong third quarter in 2025 with a 28% increase in sales compared to the same period last year, driven by significant growth in the US market and a 73% increase in Cystatin C sales. The company’s EBITDA also improved, and they are advancing their NT-proBNP project towards a commercial launch in late 2026. Additionally, Gentian’s development project with a major IVD company has progressed to the optimization phase, and they have enrolled approximately 70 patients in a study evaluating the use of GCAL in juvenile idiopathic arthritis.
More about Gentian Diagnostics ASA
Gentian Diagnostics ASA is a developer and manufacturer of high-quality in vitro diagnostic reagents, specializing in immunoassays for infections, inflammation, kidney failure, and congestive heart failure. The company focuses on converting clinically relevant biomarkers to efficient automated, high-throughput analyzers, thereby contributing to cost savings and life protection. Headquartered in Moss, Norway, Gentian serves global human and veterinary diagnostics markets with offices in Sweden, USA, and China.
Average Trading Volume: 5,250
Current Market Cap: NOK857.5M
For detailed information about 6FK stock, go to TipRanks’ Stock Analysis page.